Clinical trials: Soft-tissue Sarcomas
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01462630
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, positron emission tomography
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumors, Thyroid Cancer
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
- Conditions
- Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
- Trial name
- NCT01438554
- Testing
- Pazopanib, GSK1120212
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00937495
- Testing
- vorinostat, bortezomib
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Osteosarcoma
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer.
- Conditions
- Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT07516353
- Testing
- my.naviGATE Digital Tool
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Dana-Farber Cancer Institute
Soft Tissue Sarcoma
Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions
This randomized prospective open-label phase 2 trial testes the safety and feasibility of a hypofractionated accelerated neoadjuvant proton or carbon ion radiotherapy based on the rate of wound healing disorders from beginning of…
- Trial name
- EXTREM ION (NCT04946357)
- Testing
- Protons, carbon ions
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University Hospital Heidelberg
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Trial name
- NCT06444880
- Testing
- Ubamatamab, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
The overall goal of this Phase 2 study is to determine the efficacy of a lower dose weekly schedule of doxorubicin in patients with unresectable leiomyosarcomas aged 65-100 years old.
- Trial name
- NCT07125183
- Testing
- Doxorubicin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Leiomyosarcoma, Liposarcoma
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Osteosarcoma, Sarcoma, Soft Tissue
- Trial name
- NCT00093080
- Testing
- ridaforolimus
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Sarcoma
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) either for 12 or for 36 months following surgery.
- Trial name
- NCT00116935
- Testing
- imatinib mesylate, imatinib
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Scandinavian Sarcoma Group
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Soft Tissue Sarcoma, Bone Sarcoma
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.
- Trial name
- NCT05621668
- Testing
- Cyclophosphamide, attIL2-T cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
- Trial name
- NCT05352750
- Testing
- SON-1010
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sonnet BioTherapeutics
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Sarcoma, Kaposi, HIV Infections
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
To determine the safety as well as the most effective dose of sargramostim (GM-CSF; granulocyte-macrophage colony stimulating factor) that will prevent the side effects caused by the combined use of zidovudine (AZT) and various…
- Trial name
- NCT00000681
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RHABDOMYOSARCOMA
Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma
This is an international open-label, randomized, multicenter phase II study of VIT and VI for the treatment of patients with recurrent or refractory rhabdomyosarcoma.
- Trial name
- VIT-0910 (NCT01355445)
- Testing
- Vincristine, Irinotecan, Vincristine, Irinotecan, Temozolomide
- Where
- 16 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Oscar Lambret
Kaposi Sarcoma
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV.
- Trial name
- NCT04941274
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Dedifferentiated Liposarcoma
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in…
- Trial name
- PERELI (NCT06389799)
- Testing
- Pemigatinib, Retifanlimab
- Where
- 4 sites in Norway, Sweden
- Volunteers
- 33 people
- Sponsor
- Lund University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.